The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://saadwtqp906023.wikicarrier.com/1035146/retatrutide_vs_tirzepatide_a_comparative_analysis